Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center
Introduction/background, currently, 7 agents are approved for the first- and second-line therapy for metastatic renal cell carcinoma. In contrast, data supporting their use beyond second line are limited. Here we summarize our experience in patients treated with more than 4 lines of therapy. Methods...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2015
|
| In: |
Clinical genitourinary cancer
Year: 2014, Jahrgang: 13, Heft: 3, Pages: e145-e152 |
| ISSN: | 1938-0682 |
| DOI: | 10.1016/j.clgc.2014.12.012 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.clgc.2014.12.012 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1558767314002869 
|
| Verfasserangaben: | Sonia Vallet, Sascha Pahernik, Thomas Höfner, Georgi Tosev, Boris Hadaschik, Stefan Duensing, Oliver Sedlaczek, Markus Hohenfellner, Dirk Jäger, Carsten Grüllich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1559578505 | ||
| 003 | DE-627 | ||
| 005 | 20230428071219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170608r20152014xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2014.12.012 |2 doi | |
| 035 | |a (DE-627)1559578505 | ||
| 035 | |a (DE-576)489578500 | ||
| 035 | |a (DE-599)BSZ489578500 | ||
| 035 | |a (OCoLC)1340976036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vallet, Sonia |d 1976- |e VerfasserIn |0 (DE-588)105867207X |0 (DE-627)797396403 |0 (DE-576)414826493 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer |b retrospective analysis from a large-volume cancer center |c Sonia Vallet, Sascha Pahernik, Thomas Höfner, Georgi Tosev, Boris Hadaschik, Stefan Duensing, Oliver Sedlaczek, Markus Hohenfellner, Dirk Jäger, Carsten Grüllich |
| 264 | 1 | |c 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 30 December 2014 | ||
| 500 | |a Gesehen am 08.06.2017 | ||
| 520 | |a Introduction/background, currently, 7 agents are approved for the first- and second-line therapy for metastatic renal cell carcinoma. In contrast, data supporting their use beyond second line are limited. Here we summarize our experience in patients treated with more than 4 lines of therapy. Methods: we retrospectively assessed the outcome of 24 patients treated at our institution with at least 4 lines of therapy. Progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier estimates.Results: Median OS from the initiation of first-line therapy for the whole cohort is 64.7 months. Up to 96% of the patients received a tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor (mTOR-I) within the first 3 lines of treatment. In the fourth or following lines, patients were treated with TKI, mTOR-I, bevacizumab/interferon, or experimental drugs. Seven patients continued treatment with a sixth-line agent; one has been treated up to the ninth line. Sixteen percent of the patients receiving fourth-line therapy and 13% receiving fifth-line therapy experienced a partial remission, which was independent from response to previous therapies. Median OS from fourth and fifth line was 30.8 and 26.2 months, respectively. Median PFS for fourth-line therapy was 5.8 months. No significant difference in PFS was observed for patients with disease that responded or did not respond to first-line therapy. Conclusion: Despite the limitations of a retrospective analysis, our study suggests that selected patients benefit from multiple lines of treatment, independent of response to first-line therapy. However, the optimal sequence of treatment with regard to later lines remains to be determined. | ||
| 534 | |c 2014 | ||
| 650 | 4 | |a Metastatic kidney cancer | |
| 650 | 4 | |a Multiple lines of treatment | |
| 650 | 4 | |a Objective response | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Targeted therapy | |
| 700 | 1 | |a Pahernik, Sascha |d 1968- |e VerfasserIn |0 (DE-588)122063163 |0 (DE-627)081713495 |0 (DE-576)293073147 |4 aut | |
| 700 | 1 | |a Tosev, Georgi |e VerfasserIn |0 (DE-588)1098138333 |0 (DE-627)857783084 |0 (DE-576)468966455 |4 aut | |
| 700 | 1 | |a Hadaschik, Boris |d 1974- |e VerfasserIn |0 (DE-588)124300553 |0 (DE-627)085770930 |0 (DE-576)294109013 |4 aut | |
| 700 | 1 | |a Duensing, Stefan |d 1967- |e VerfasserIn |0 (DE-588)1074044487 |0 (DE-627)830213007 |0 (DE-576)435550098 |4 aut | |
| 700 | 1 | |a Sedlaczek, Oliver |d 1970- |e VerfasserIn |0 (DE-588)123144493 |0 (DE-627)706179838 |0 (DE-576)293576173 |4 aut | |
| 700 | 1 | |a Hohenfellner, Markus |d 1958- |e VerfasserIn |0 (DE-588)133862518 |0 (DE-627)557857988 |0 (DE-576)300155263 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Grüllich, Carsten |d 1965- |e VerfasserIn |0 (DE-588)14101914X |0 (DE-627)624500985 |0 (DE-576)321797981 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d Dallas, Tex. : CIG Media Group, 2005 |g 13(2015), 3, Seite e145-e152 |h Online-Ressource |w (DE-627)585792658 |w (DE-600)2466266-5 |w (DE-576)358411122 |x 1938-0682 |7 nnas |a Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer retrospective analysis from a large-volume cancer center |
| 773 | 1 | 8 | |g volume:13 |g year:2015 |g number:3 |g pages:e145-e152 |g extent:8 |a Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer retrospective analysis from a large-volume cancer center |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2014.12.012 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1558767314002869 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170608 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 14101914X |a Grüllich, Carsten |m 14101914X:Grüllich, Carsten |d 910000 |d 910100 |e 910000PG14101914X |e 910100PG14101914X |k 0/910000/ |k 1/910000/910100/ |p 10 |y j | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 9 | ||
| 998 | |g 133862518 |a Hohenfellner, Markus |m 133862518:Hohenfellner, Markus |d 910000 |d 910200 |e 910000PH133862518 |e 910200PH133862518 |k 0/910000/ |k 1/910000/910200/ |p 8 | ||
| 998 | |g 123144493 |a Sedlaczek, Oliver |m 123144493:Sedlaczek, Oliver |d 910000 |d 911400 |e 910000PS123144493 |e 911400PS123144493 |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 1074044487 |a Duensing, Stefan |m 1074044487:Duensing, Stefan |d 910000 |d 910200 |e 910000PD1074044487 |e 910200PD1074044487 |k 0/910000/ |k 1/910000/910200/ |p 6 | ||
| 998 | |g 124300553 |a Hadaschik, Boris |m 124300553:Hadaschik, Boris |d 910000 |d 910200 |e 910000PH124300553 |e 910200PH124300553 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 998 | |g 1098138333 |a Tosev, Georgi |m 1098138333:Tosev, Georgi |d 910000 |d 910200 |e 910000PT1098138333 |e 910200PT1098138333 |k 0/910000/ |k 1/910000/910200/ |p 4 | ||
| 998 | |g 122063163 |a Pahernik, Sascha |m 122063163:Pahernik, Sascha |d 910000 |d 910200 |e 910000PP122063163 |e 910200PP122063163 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 998 | |g 105867207X |a Vallet, Sonia |m 105867207X:Vallet, Sonia |d 910000 |d 910100 |e 910000PV105867207X |e 910100PV105867207X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1559578505 |e 2971498328 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"585792658","disp":"Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer retrospective analysis from a large-volume cancer centerClinical genitourinary cancer","part":{"pages":"e145-e152","volume":"13","extent":"8","issue":"3","year":"2015","text":"13(2015), 3, Seite e145-e152"},"pubHistory":["4.2005/06,3 -"],"id":{"zdb":["2466266-5"],"eki":["585792658"],"issn":["1938-0682"]},"origin":[{"dateIssuedKey":"2005","publisherPlace":"Dallas, Tex.","dateIssuedDisp":"2005-","publisher":"CIG Media Group"}],"note":["Gesehen am 14.04.25"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title":"Clinical genitourinary cancer","title_sort":"Clinical genitourinary cancer"}]}],"person":[{"role":"aut","display":"Vallet, Sonia","family":"Vallet","given":"Sonia"},{"display":"Pahernik, Sascha","family":"Pahernik","role":"aut","given":"Sascha"},{"given":"Georgi","role":"aut","family":"Tosev","display":"Tosev, Georgi"},{"given":"Boris","family":"Hadaschik","display":"Hadaschik, Boris","role":"aut"},{"role":"aut","display":"Duensing, Stefan","family":"Duensing","given":"Stefan"},{"given":"Oliver","role":"aut","display":"Sedlaczek, Oliver","family":"Sedlaczek"},{"given":"Markus","role":"aut","display":"Hohenfellner, Markus","family":"Hohenfellner"},{"given":"Dirk","role":"aut","family":"Jäger","display":"Jäger, Dirk"},{"given":"Carsten","display":"Grüllich, Carsten","family":"Grüllich","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2015","dateIssuedKey":"2015"}],"recId":"1559578505","id":{"doi":["10.1016/j.clgc.2014.12.012"],"eki":["1559578505"]},"note":["Published online: 30 December 2014","Gesehen am 08.06.2017"],"name":{"displayForm":["Sonia Vallet, Sascha Pahernik, Thomas Höfner, Georgi Tosev, Boris Hadaschik, Stefan Duensing, Oliver Sedlaczek, Markus Hohenfellner, Dirk Jäger, Carsten Grüllich"]},"title":[{"title":"Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer","subtitle":"retrospective analysis from a large-volume cancer center","title_sort":"Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer"}],"language":["eng"],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a VALLETSONIEFFICACYOF2015 | ||